Print Page | Contact Us | Report Abuse | Sign In | Register
Webinar: The Patient-Centered Approach to Extended-Release Naltrexone (XR-NTX)
Tell a Friend About This EventTell a Friend
 

Webinar participants will review XR-NTX’s pharmacology, clinical indication, formulation, patient selection issues, patient initiation protocols, counseling approaches, contraindications, adverse effects, and considerations regarding treatment completion

 Export to Your Calendar 4/30/2018
When: Monday, 04/30/2018
10:30 AM - 12:30 PM
Where: United States
Presenter: David R. Gastfriend, MD
Contact: Lee Ann Griffin
(850) 878-2196

« Go to Upcoming Event List  

 
The FDA approved intramuscular Extended-Release Naltrexone (XR-NTX) for the prevention of relapse in opioid use disorder (OUD) following detoxification. XR-NTX is different from previous Medications in Addiction Treatment (MAT) in terms of abstinence & blockade, duration of action, psychological effects, and impact on behavior. We will review XR-NTX’s pharmacology, clinical indication, formulation, patient selection issues, patient initiation protocols, counseling approaches, contraindications, adverse effects, and considerations regarding treatment completion

Who should attend?
This training is relevant to a variety of health and human service professionals and paraprofessionals, such as health care professionals (physicians, pharmacists, nurses, emergency medical personnel, etc.), law enforcement, mental health and addiction professionals, behavioral health technicians, recovery support personnel, and community members at risk of experiencing or witnessing an opioid overdose.

Presented by: 
David Gastfriend, MD, is Senior Research Scientist at the Treatment Research Institute (TRI). An addiction psychiatrist, he directed addiction research at Massachusetts General Hospital and was an investigator in the NIDA Cocaine Collaborative Study, the NIAAA COMBINE Study and the NIDA Clinical Trials Network.As Vice President at Alkermes, Inc., Dr. Gastfriend conducted biological, clinical, health economics and policy research on behalf of the company’s efforts in the field of addiction treatment. For 25 years, Dr. Gastfriend served on the faculty of Harvard Medical School, notably as the Director of the Addiction Research Program at Massachusetts General Hospital and founder of the MGH/McLean Hospital Fellowship in Addiction Psychiatry. He is considered the world’s leading expert on two important treatment tools from both the biological and psychosocial realms: the opioid blocker Vivitrol, and the American Society of Addiction Medicine (ASAM) Criteria Software.

 
CEUs:
2 Continuing Education Units/Contact Hours are provided for this event
Florida Certification Board Approved Education Provider, #001-A
Florida Board of Social Work, Marriage and Family Therapy and Mental Health Counseling Provider #50-676
Florida Board of Nursing Provider #50-676